Protalix up on positive data from genetic disorder therapy study

PLx Pharma Winddown

04/04/2022 12:19

** U.S.-listed shares of Israeli drug developer  PLX.TA ,
 PLX.N  rise ~17% to $1.23 premarket
    ** PLX reports positive data from 24-month late-stage study
of PRX–102 in patients with Fabry disease previously treated
with another therapy called Agalsidase beta 
    ** Fabry disease is a rare genetic disorder that causes a
range of symptoms, including a progressive impairment of kidneys
leading to renal failure
    ** PRX-102 met main goal of non-inferiority in kidney
function vs agalsidase beta
    ** Marketing application resubmission to U.S. FDA planned
for H2 of 2022
    ** PLX has risen 26.25% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))